Key facts
- This page summarizes Matthew Gregory Cohen's Form 4 filing for ARROWHEAD PHARMACEUTICALS, INC. (ARWR).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 17 Jun 2026, 21:44.
Matthew Gregory Cohen - 15 Jun 2026 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)
- Reporting relationship
- Director
- Issuer ticker
- ARWR
- Reported as of
- 15 Jun 2026
- Net transaction value
- $0
- Reporting owner signature
- /s/Matthew Gregory Cohen
Source evidence
Original filing metadata and source links for verification.
3 source fields
Reporting owner
1 detail
Key filing fact
Matthew Gregory Cohen filed Form 4 for ARROWHEAD PHARMACEUTICALS, INC. (ARWR) on 17 Jun 2026.
Change
- No earlier filing in this sequence is available for direct comparison.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reporting Owners (1)
CIK 0002141314
Primary reporting owner
Cohen Matthew Gregory
- Relationship
- Director
- Address
- 177 EAST COLORADO BLVD STE 700, PASADENA
- Signature
- /s/Matthew Gregory Cohen
- Signature date
- 17 Jun 2026
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ARWR
transaction
Common Stock
Award
- Transaction value
- Shares
- +11,882
- Change %
- Price
- $0.000000*
- Shares after
- 11,882
- Date
- 15 Jun 2026
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
Represents shares underlying restricted stock units with a grant date 06/15/2026, which will vest over three years.